{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:40:11Z","timestamp":1788964811347,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s42000-020-00256-0","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T08:03:02Z","timestamp":1604563382000},"page":"369-376","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Diabetic ketoacidosis in patients treated with SGLT2 inhibitors: experience at a tertiary hospital"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8587-7797","authenticated-orcid":false,"given":"Labrini","family":"Papanastasiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridoula","family":"Glycofridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Gravvanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikitas","family":"Skarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Papadimitriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Kanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chara","family":"Kapsali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Kounadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,5]]},"reference":[{"key":"256_CR1","doi-asserted-by":"publisher","first-page":"362","DOI":"10.15585\/mmwr.mm6712a3","volume":"67","author":"SR Benoit","year":"2018","unstructured":"Benoit SR, Zhang Y, Geiss LS, Gregg EW, Albright A (2018) Trends in diabetic ketoacidosis hospitalizations and in-hospital mortality - United States, 2000-2014. MMWR Morb Mortal Wkly Rep 67:362\u2013365. https:\/\/doi.org\/10.15585\/mmwr.mm6712a3","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"256_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2337\/dc09-9032","volume":"32","author":"AE Kitabchi","year":"2009","unstructured":"Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN (2009) Hyperglycemic crises in adult patients with diabetes. Diabetes Care 32:1335\u20131343. https:\/\/doi.org\/10.2337\/dc09-9032","journal-title":"Diabetes Care"},{"key":"256_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4158\/CS-2019-0472","volume":"26","author":"AJ Garber","year":"2020","unstructured":"Garber AJ, Handelsman Y, Grunberger G et al (2020) Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2020 executive summary. Endocr Pract 26:107\u2013139. https:\/\/doi.org\/10.4158\/CS-2019-0472","journal-title":"Endocr Pract"},{"key":"256_CR4","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s40265-018-0901-y","volume":"78","author":"H Fattah","year":"2018","unstructured":"Fattah H, Vallon V (2018) The potential role of SGLT2 inhibitors in the treatment of type 1 diabetes mellitus. Drugs 78:717\u2013726. https:\/\/doi.org\/10.1007\/s40265-018-0901-y","journal-title":"Drugs"},{"key":"256_CR5","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132212. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"256_CR6","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323\u2013334. https:\/\/doi.org\/10.1056\/NEJMoa1515920","journal-title":"N Engl J Med"},{"key":"256_CR7","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"256_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"256_CR9","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1210\/jc.2015-1884","volume":"100","author":"SI Taylor","year":"2015","unstructured":"Taylor SI, Blau JE, Rother KI (2015) SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 100:2849\u20132852. https:\/\/doi.org\/10.1210\/jc.2015-1884","journal-title":"J Clin Endocrinol Metab"},{"key":"256_CR10","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.2337\/dc15-1251","volume":"38","author":"N Erondu","year":"2015","unstructured":"Erondu N, Desai M, Ways K, Meininger G (2015) Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 38:1680\u20131686. https:\/\/doi.org\/10.2337\/dc15-1251","journal-title":"Diabetes Care"},{"key":"256_CR11","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.2337\/dc15-1730","volume":"38","author":"RR Henry","year":"2015","unstructured":"Henry RR, Thakkar P, Tong C, Polidori D, Alba M (2015) Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type I diabetes. Diabetes Care 38:2258\u20132265. https:\/\/doi.org\/10.2337\/dc15-1730","journal-title":"Diabetes Care"},{"key":"256_CR12","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1210\/jc.2019-00139","volume":"104","author":"PS Hamblin","year":"2019","unstructured":"Hamblin PS, Wong R, Ekinci EI et al (2019) SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission. J Clin Endocrinol Metab 104:3077\u20133087. https:\/\/doi.org\/10.1210\/jc.2019-00139","journal-title":"J Clin Endocrinol Metab"},{"key":"256_CR13","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2337\/dc15-0843","volume":"38","author":"AL Peters","year":"2015","unstructured":"Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB (2015) Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter2 inhibition. Diabetes Care 38:1687\u20131693. https:\/\/doi.org\/10.2337\/dc15-0843","journal-title":"Diabetes Care"},{"key":"256_CR14","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.2337\/dc17-1721","volume":"41","author":"EJ Meyer","year":"2018","unstructured":"Meyer EJ, Gabb G, Jesudason D (2018) SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis: a South Australian clinical case series and Australian spontaneous adverse event notifications. Diabetes Care 41:e47\u2013e49. https:\/\/doi.org\/10.2337\/dc17-1721","journal-title":"Diabetes Care"},{"key":"256_CR15","doi-asserted-by":"publisher","first-page":"k4365","DOI":"10.1136\/bmj.k4365","volume":"363","author":"P Ueda","year":"2018","unstructured":"Ueda P, Svanstr\u00f6m H, Melbye M et al (2018) Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ 363:k4365. https:\/\/doi.org\/10.1136\/bmj.k4365","journal-title":"BMJ"},{"key":"256_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1463423618000476","volume":"23","author":"L Patakfalvi","year":"2018","unstructured":"Patakfalvi L, Brazeau AS, Dasgupta K (2018) Physician experiences with sodium-glucose cotransporter (SGLT2) inhibitors, a new class of medications in type 2 diabetes, and adverse effects. Prim Health Care Res Dev 23:1\u20136. https:\/\/doi.org\/10.1017\/S1463423618000476","journal-title":"Prim Health Care Res Dev"},{"key":"256_CR17","doi-asserted-by":"publisher","unstructured":"Blau JE, Tella SH, Taylor SI, Rother KI (2017) Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data. Diabetes Metab Res Rev 33(8). https:\/\/doi.org\/10.1002\/dmrr.2924","DOI":"10.1002\/dmrr.2924"},{"key":"256_CR18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/jdi.12330","volume":"6","author":"T Hayami","year":"2015","unstructured":"Hayami T, Kato Y, Kamiya H et al (2015) Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet. J Diabetes Investig 6:587\u2013590. https:\/\/doi.org\/10.1111\/jdi.12330","journal-title":"J Diabetes Investig"},{"key":"256_CR19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S2213-8587(15)00204-1","volume":"3","author":"J Hine","year":"2015","unstructured":"Hine J, Paterson H, Abrol E et al (2015) SGLT inhibition and euglycaemic diabetic ketoacidosis. Lancet Diabetes Endocrinol 3:503\u2013504. https:\/\/doi.org\/10.1016\/S2213-8587(15)00204-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"256_CR20","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.2337\/dc15-1797","volume":"39","author":"P Roach","year":"2016","unstructured":"Roach P, Skierczynski P (2016) Euglycemic diabetic ketoacidosis in a patient with type 2 diabetes after treatment with empagliflozin. Diabetes Care 39:e3. https:\/\/doi.org\/10.2337\/dc15-1797","journal-title":"Diabetes Care"},{"key":"256_CR21","doi-asserted-by":"publisher","unstructured":"Lucero P, Chapela S (2018) Euglycemic diabetic ketoacidosis in the ICU: 3 case reports and review of literature. Case Rep Crit Care 1747850. https:\/\/doi.org\/10.1155\/2018\/1747850","DOI":"10.1155\/2018\/1747850"},{"key":"256_CR22","doi-asserted-by":"publisher","first-page":"e6089","DOI":"10.7759\/cureus.6089","volume":"11","author":"I Iqbal","year":"2019","unstructured":"Iqbal I, Hamid M, Khan MAA, Kainat A, Tariq S (2019) Dapagliflozin-induced late-onset euglycemic diabetic ketoacidosis. Cureus. 11:e6089. https:\/\/doi.org\/10.7759\/cureus.6089","journal-title":"Cureus."},{"key":"256_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12245-019-0240-0","volume":"12","author":"A Diaz-Ramos","year":"2019","unstructured":"Diaz-Ramos A, Eilbert W, Marquez D (2019) Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature. Int J Emerg Med 12:27. https:\/\/doi.org\/10.1186\/s12245-019-0240-0","journal-title":"Int J Emerg Med"},{"key":"256_CR24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.5694\/mja2.50302","volume":"211","author":"G McLachlan","year":"2019","unstructured":"McLachlan G, Keith C, Frauman A (2019) Diabetic ketoacidosis with sodium-glucose cotransporter type 2 inhibitors: a case series. Med J Aust 211:237\u2013237.e1. https:\/\/doi.org\/10.5694\/mja2.50302","journal-title":"Med J Aust"},{"key":"256_CR25","doi-asserted-by":"publisher","unstructured":"Dorcely B, Nitis J, Schwartzbard A et al (2020) A case report: euglycemic diabetic ketoacidosis presenting as chest pain in a patient on a low carbohydrate diet. Curr Diabetes Rev. https:\/\/doi.org\/10.2174\/1573399816666200316112709","DOI":"10.2174\/1573399816666200316112709"},{"issue":"Suppl 2","key":"256_CR26","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.2337\/dcS15-3006","volume":"39","author":"P Fioretto","year":"2016","unstructured":"Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R (2016) SGLT2 inhibitors and the diabetic kidney. Diabetes Care 39(Suppl 2):S165\u2013S171. https:\/\/doi.org\/10.2337\/dcS15-3006","journal-title":"Diabetes Care"},{"key":"256_CR27","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","volume":"27","author":"JE Gerich","year":"2010","unstructured":"Gerich JE (2010) Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 27:136\u2013142. https:\/\/doi.org\/10.1111\/j.1464-5491.2009.02894.x","journal-title":"Diabet Med"},{"key":"256_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrendo.2015.51","volume":"11","author":"JE Campbell","year":"2015","unstructured":"Campbell JE, Drucker DJ (2015) Islet \u03b1 cells and glucagon-critical regulators of energy homeostasis. Nat Rev Endocrinol 11:329\u2013338. https:\/\/doi.org\/10.1038\/nrendo.2015.51","journal-title":"Nat Rev Endocrinol"},{"key":"256_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1053\/jcrc.2002.33030","volume":"17","author":"G Umpierrez","year":"2002","unstructured":"Umpierrez G, Freire AX (2002) Abdominal pain in patients with hyperglycemic crises. J Crit Care 17:63\u201367. https:\/\/doi.org\/10.1053\/jcrc.2002.33030","journal-title":"J Crit Care"},{"key":"256_CR30","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.diabet.2019.01.001","volume":"45","author":"JY Jeon","year":"2019","unstructured":"Jeon JY, Kim SK, Kim KS et al (2019) DKA Study Group of Gyeonin Branch of the Korean Diabetes Association Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors. Diabetes Metab 45:453\u2013457. https:\/\/doi.org\/10.1016\/j.diabet.2019.01.001","journal-title":"Diabetes Metab"},{"key":"256_CR31","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1016\/j.clinthera.2016.11.002","volume":"38","author":"RM Goldenberg","year":"2016","unstructured":"Goldenberg RM, Berard LD, Cheng AYY et al (2016) SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther 38:2654\u20132664.e1. https:\/\/doi.org\/10.1016\/j.clinthera.2016.11.002","journal-title":"Clin Ther"},{"key":"256_CR32","doi-asserted-by":"publisher","first-page":"753","DOI":"10.4158\/EP161292.PS","volume":"22","author":"Y Handelsman","year":"2016","unstructured":"Handelsman Y, Henry RR, Bloomgarden ZT et al (2016) American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract 22:753\u2013762. https:\/\/doi.org\/10.4158\/EP161292.PS","journal-title":"Endocr Pract"},{"key":"256_CR33","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.2337\/dc18-2316","volume":"42","author":"T Danne","year":"2019","unstructured":"Danne T, Garg S, Peters AL et al (2019) International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care 42:1147\u20131154. https:\/\/doi.org\/10.2337\/dc18-2316","journal-title":"Diabetes Care"},{"key":"256_CR34","doi-asserted-by":"publisher","first-page":"EDM190087","DOI":"10.1530\/EDM-19-0087","volume":"19-0087","author":"MF Rafey","year":"2019","unstructured":"Rafey MF, Butt A, Coffey B et al (2019) Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis. Endocrinol Diabetes Metab Case Rep 19-0087:EDM190087. https:\/\/doi.org\/10.1530\/EDM-19-0087","journal-title":"Endocrinol Diabetes Metab Case Rep"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-020-00256-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-020-00256-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-020-00256-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T02:13:07Z","timestamp":1620699187000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-020-00256-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,5]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["256"],"URL":"https:\/\/doi.org\/10.1007\/s42000-020-00256-0","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,5]]},"assertion":[{"value":"8 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol is approved from the Scientific Committee of the General Hospital of Athens \u2018G Gennimatas\u2019, Greece (reference number 15238\/30.06.2020), and the reporting of the study conforms to the Guidelines for Good Clinical Practice, the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent for research and scientific reasons is routinely collected from each patient admitted to the Endocrinology Unit.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}